Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Corindus touts high success rate in CorPath 200 PCI registry study
Corindus Vascular Robotics today released post-market findings from the Precision registry study of its CorPath 200 system used during percutaneous coronary interventions, touting high clinical and technical success rates.
Data from the registry study was presented at the 2017 Society for Cardiovascular Angiography and Interventions Scientific Sessions last Friday, the Waltham, Mass.-based company said. Read more
4. Medtronic looks to settle TAVR patent spat with doc inventor
Medtronic is looking to settle a patent infringement dispute over transcatheter aortic valve replacements with a doctor who sued the company and cross-town rival St. Jude Medical, which last week lost its bid to have the case dismissed.
Dr. Robert Snyder, founder of Snyders Heart Valve, filed suits last year in the U.S. District Court for Eastern Texas claiming that both companies used technologies covered by his patents for an artificial heart valve and delivery system called the Funnel valve, according to court documents. The lawsuits, which were later consolidated, allege that St. Jude’s Portico valve and Medtronic CoreValve and CoreValve Evolut implants infringe a pair of his patents. Read more
3. Boston Scientific closes $435m Symetis buyout
Boston Scientific said today that it closed its $435 million buyout of Symetis and its line of minimally invasive replacement heart valves.
The buyout, announced in March, halted the 2nd run at an initial public offering by Symetis, which launched the IPO March 20 in a bid to raise up to $66 million (€61.5 million) on the Euronext exchange in Paris. The Ecublens, Switzerland-based company, which acquired Middle Peak Medical and its transcatheter mitral valve implant just last month, spiked its 1st $96 million IPO attempt in September 2015. Symetis employs about 300 workers worldwide. Boston Scientific executives have said the company isn’t interested in the Middle Peak assets, which are slated for a spin-out ahead of the deal’s closing. Read more
2. EuroPCR 2017 Roundup: Boston Scientific’s Lotus beats Medtronic’s CoreValve in head-to-head study
Boston Scientific said its Lotus replacement heart valve beat the competing CoreValve device made by Medtronic in a head-to-head trial.
Data from the Reprise III study, billed as the 1st head-to-head pivotal trial comparing transcatheter aortic valve replacements, were released today at the annual EuroPCR meeting in Paris. The 912-patient study compared Lotus with the CoreValve and CoreValve Evolut devices in high- and extreme-risk patients. Read more
1. Abbott recalls heart catheters on balloon sheath issue
Abbott is recalling some 450,000 coronary catheters on the risk that removing a protective balloon sheath can damage the ballon during angioplasty procedures.
In a March 22 letter to customers, Abbot said the recall affects its NC Trek RX and NC Traveler RX coronary dilatation catheters and the NC Tenku RX PTCA balloon catheter. Read more